-

02:34:30 PM

MDNA Stock News

MDNA - Medicenna Therapeutics Corp

09/28/23 5:00 PM

Nasdaq : MDNA

Medicenna Announces Results of Annual and Special Meeting of Shareholders

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company’s annual and

RHEA-AI

neutral

09/28/23 7:00 AM

Nasdaq : MDNA

conferences

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its

RHEA-AI

neutral

09/06/23 7:00 AM

Nasdaq : MDNA

conferences

Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that Dr. Fahar Merchant, President and CEO is scheduled to

RHEA-AI

neutral

08/28/23 7:00 AM

Nasdaq : MDNA

management

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leading

RHEA-AI

neutral

08/14/23 7:00 AM

Nasdaq : MDNA

management

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in

RHEA-AI

positive

08/09/23 7:30 AM

Nasdaq : MDNA

clinical trial

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11 -

RHEA-AI

neutral

08/08/23 7:00 AM

Nasdaq : MDNA

management

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the

RHEA-AI

neutral

08/04/23 7:00 AM

Nasdaq : MDNA

clinical trial

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a

RHEA-AI

neutral

08/01/23 9:30 AM

Nasdaq : MDNA

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.” The patent covers a method for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving fitness of cancer fighting immune cells.

RHEA-AI

positive

07/28/23 7:00 AM

Nasdaq : MDNA

earnings

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicities MDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose for

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

MDNA Data

IndustryPharmaceutical Preparation Manufacturing
Websitemedicenna.com
Security nameMedicenna Therapeutics Corp
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About Medicenna Therapeutics Corp

medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca